ASYMCHEM Stock Code: 002821 Stock Abbreviation: Kairui Ying Announcement No.: 2026-001 Kairui Ying Pharmaceutical Group (Tianjin) Co., Ltd. Announcement of Resolutions of the Seventh Meeting of the Fifth Board of Directors The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed herein, and are free from any false representations, misleading statements, or material omissions.
I. Convening of the Board Meeting
The notice for the Seventh Meeting of the Fifth Board of Directors of Kairui Ying Pharmaceutical Group (Tianjin) Co., Ltd. (hereinafter referred to as the "Company") was sent to all directors and senior management via email and in writing on March 6, 2026. The meeting was held via communication on March 13, 2026. A total of 9 directors were eligible to attend, and 9 directors attended. Some of the Company's senior management personnel attended the meeting. The meeting was convened and presided over by Mr. HAO HONG, Chairman of the Company. The convening and holding of this meeting comply with the provisions of the "Company Law" and relevant laws, regulations, and the "Articles of Association."
II. Review of Proposals by the Board of Directors
The meeting was held via communication. After deliberation and voting by all attending directors, the following resolutions were passed:
- Review and Approval of the "Proposal on Repurchasing and Cancelling Part of the Restricted Shares under the 2025 A Share Restricted Share Incentive Plan"
According to the relevant provisions of the Company's "2025 A Share Restricted Share Incentive Plan": "Where a grantee resigns or is terminated by the Company, the restricted shares granted but not yet vested held by the grantee shall not be vested and shall be repurchased and cancelled by the Company at the grant price." Therefore, a total of 61,000 restricted shares, including those granted but not yet vested to 4 initial grantees who have resigned and 1 reserved grantee who has resigned, will be repurchased and cancelled by the Company. This matter has been reviewed and approved by the first meeting of the Remuneration and Assessment Committee in 2026. Voting results: 9 votes in favor, 0 votes against, 0 abstentions. The meeting agreed to this proposal, which will be submitted to the first extraordinary general meeting in 2026 and the first A share class meeting in 2026.